Last reviewed 2026-05-14 · How we verify

6-tioguanine+Standard Maintenance Therapy (6-tioguanine-standard-maintenance-therapy)

At a glance

Approved indications

• Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies
• Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies
• Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies
• Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies
• Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies
• Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies
• Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies
• Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies
• Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies
• Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies
• Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies
• Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies
• Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies
• Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies
• Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies
• Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies
• Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies
• Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies
• Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies
• Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies

Common side effects

No common side effects on file.

Drug interactions

• Allopurinol
• Azathioprine
• Cyclophosphamide
• Fludarabine
• Methotrexate
• Pentostatin
• Warfarin
• Cyclosporine
• Tacrolimus
• Live vaccines

Key clinical trials

• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
• Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia (PHASE1)
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (PHASE3)
• Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 (PHASE3)
• Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma (PHASE3)
• International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma (PHASE3)
• Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL (PHASE2, PHASE3)
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• 6-tioguanine+Standard Maintenance Therapy CI brief — competitive landscape report
• 6-tioguanine+Standard Maintenance Therapy updates RSS · CI watch RSS
• Pfizer portfolio CI